Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 6/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324496 | 0.90 | MAPT (0.38) | DPP4HPGD | |
| SCHEMBL648876 | 0.82 | DPP4 (0.43) | MTNR1AMTNR1BSIRT1DPP4HPGD | |
| SCHEMBL653007 | 0.81 | BRD4 (0.47) | MTNR1AMTNR1BSIRT1DPP4HPGD | |
| SCHEMBL10148387 | 0.81 | MTNR1A (0.42) | MTNR1AMTNR1BSIRT1ALOX12BRS3 | |
| SCHEMBL31043514 | 0.80 | MTNR1A (0.53) | MTNR1AMTNR1BSIRT1ALOX12DPP4 | |
| SCHEMBL430079 | 0.80 | MTNR1A (0.53) | MTNR1AMTNR1BSIRT1ALOX12DPP4 | |
| SCHEMBL12894301 | 0.78 | FNTA (0.51) | MTNR1AMTNR1B | |
| SCHEMBL7246204 | 0.78 | FNTA (0.46) | SIRT1 | |
| SCHEMBL652622 | 0.78 | AADAT (0.44) | MTNR1AMTNR1BSIRT1DPP4BRS3 | |
| SCHEMBL651795 | 0.78 | FNTA (0.46) | SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | MTNR1A 173/4885MTNR1B 74/4885SIRT1 1086/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | MTNR1A 121/4885MTNR1B 44/4885SIRT1 718/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | MTNR1A 173/4885MTNR1B 74/4885SIRT1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.